Astrea Bioseparations

#AAV #Astrea Bioseparations #Cell and gene therapy #Exosomes #Molecular Biology

The democratisation of cell and gene therapy

Marc Hummersone, Senior Director of Research and Development (R&D) at Astrea Bioseparations, shares insight on the challenges and opportunities in cell and gene therapy (CGT) with DDW’s Megan Thomas. Lack of standardisation According to Hummersone, the major challenge in the CGT space is a lack of throughput that’s due to… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Advertorial #Astrea Bioseparations #Bioprocessing #Cell and gene therapy #Nanofiber technology

Nanofiber technology enabling the future of CGT bioprocessing

This paid-for advertorial by Astrea Bioseparations appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 - Cell and Gene Therapy Guide. Therapeutic developers face significant challenges in purifying cell and gene therapy (CGT) modalities. Current processes rely on solutions developed for monoclonal antibodies that are not fit for purpose… Read More

#Exclusive Content